Table 2

Correlation between EST immunoreactivity and other parameters in human endometrial carcinoma

EST expressionP
+ (n = 22)− (n = 54)
ER LI (%)48.0 ± 12.254.6 ± 15.8N.S.
PR LI (%)44.2 ± 12.036.2 ± 9.1N.S.
Ki67 LI (%)27.6 ± 12.930.3 ± 11.6N.S.
Age (years)45.3 ± 8.446.8 ± 7.2N.S.
Grade 11023
Grade 2620
Grade 3611N.S.
Overall survival (5 years)91.2%85.3%N.S.
Disease-free survival (5 years)83.3%79.4%N.S.
  • NOTE. All data except for grade and survival are presented as mean ± 95% confidence interval.

  • Abbreviations: EST, estrogen sulfotransferase; N.S., not significant; ER, estrogen receptor; PR, progesterone receptor.